by Meaghan Kniffen-Wingo | Jan 9, 2025 | Press Release
Genascence Announces Six-Month Results from Phase 1b DONATELLO Trial Indicating GNSC-001 Was Safe and Well Tolerated Across Multiple Dosing Arms Read...
by Meaghan Kniffen-Wingo | Nov 12, 2024 | Press Release
Genascence Granted FDA Fast Track Designation for GNSC-001 in Patients with Osteoarthritis (OA) of the Knee Read...
by Meaghan Kniffen-Wingo | Oct 29, 2024 | Press Release
Genascence Appoints Jeymi Tambiah as Chief Medical Officer Read...
by Rachel Black | Jan 3, 2024 | Press Release
Genascence Announces Initiation of Phase 1b Clinical Trial of GNSC-001 Gene Therapy for Knee Osteoarthritis (OA) Read...
by Rachel Black | Dec 20, 2023 | Press Release
Genascence to Present at Biotech Showcase 2024 Read...
by Rachel Black | Oct 24, 2023 | Press Release
Genascence to Present Full Data from Phase 1 Clinical Trial on GNSC-001, Company’s Lead Program in Osteoarthritis, at European Society of Gene & Cell Therapy 30 th Annual Congress Read...
Recent Comments